Data as of Q4 2025 (Dec 31, 2025)

Humacyte, Inc.

(HUMA)

Financial Statements · SEC EDGAR XBRL

Revenue
$2.0M
Net Income
-$40.8M
+72.5%
EPS
$-0.26
+79.4%
Gross Margin
-376.1%
Op. Income
-$108.1M
+5.5%
FCF
-$105.9M
-6.3%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$2.0M
$0
-
-
-
$2.0M
$0
-
-
-
$9.7M
$0
-
-
-
-$7.7M
-
-
-
-
$69.3M
$88.6M
$76.5M
$63.3M
$61.3M
-
$114.4M
$100.0M
$86.1M
$82.5M
-$108.1M
-$114.4M
-$100.0M
-$84.6M
-$81.2M
-
-
$6.6M
$6.2M
$4.3M
$67.3M
-$34.3M
-$10.7M
$72.6M
$54.7M
-$40.8M
-
-
-
-
$0
$0
$0
$0
$0
-$40.8M
-$148.7M
-$110.8M
-$12.0M
-$26.5M
$-0.26
$-1.26
$-1.07
$-0.12
$-0.66
$-0.26
$-1.26
$-1.07
$-0.12
$-0.66
158.2M
118.5M
103.4M
103.1M
40.0M